As the COVID-19 pandemic shakes up some of the country’s biggest real estate markets, developers and lenders are looking to put money in places likely to weather the coming fluctuations. Josh Zegen, Managing Principal and Co-Founder at private equity firm Madison Realty Capital, made the case for New Jersey as a safe harbor for investment, particularly due to the Garden State’s density of life sciences firms. Because employees of biotech and pharmaceutical companies must still commute to laboratories, “you can’t just have your office in your home for lab work,” which Zegen believes will make multifamily and office development in New Jersey a winning proposition for the future.

Read Full Article